United States Atherectomy Devices Market Report by Product Type, Application, End User, States and Company Analysis, 2026-2034

United States Atherectomy Devices Market: Future Outlook, Growth Trends & Forecast (2026–2034)

United States Atherectomy Devices Market is expected to reach US$ 1,140.66 Million by 2034 from US$ 708.73 Million in 2025, with a CAGR of 5.43% from 2026 to 2034. The United States atherectomy devices market is driven by the growing burden of peripheral artery disease, diabetes, and vascular calcification, alongside rising adoption of minimally invasive procedures. Technological advances in laser, directional, orbital, and rotational systems are also expanding treatment options.

United States Atherectomy Devices Industry Landscape

Atherectomy devices are minimally invasive medical instruments used to remove or modify plaque buildup inside narrowed or blocked arteries. During an atherectomy procedure, a catheter-mounted cutting, rotating, orbital, or laser mechanism targets atherosclerotic material, helping restore or improve blood flow. These devices are commonly used in peripheral artery disease and selected cardiovascular interventions where heavily calcified or obstructive lesions may limit the effectiveness of balloon angioplasty or stenting alone. Major technologies include directional, rotational, orbital, and laser atherectomy systems. By facilitating vessel preparation and plaque modification, atherectomy devices can support revascularization procedures and expand treatment possibilities for complex arterial lesions.

The United States atherectomy devices market is benefiting from the substantial prevalence of peripheral artery disease (PAD), particularly among older adults and people with diabetes, hypertension, high cholesterol, and a history of smoking. Increasing recognition of complex and calcified lesions is encouraging physicians to consider plaque-modification technologies during peripheral interventions. At the same time, minimally invasive treatment approaches are gaining importance because they can support revascularization without conventional open surgery. Greater physician familiarity, expanding clinical evidence, and innovation in laser and mechanical atherectomy platforms are further supporting market development.

Recent Breakthroughs Shaping the United States Atherectomy Devices Industry

• In March 2026, the FDA approved a PMA supplement for Boston Scientific's ROTAPRO Rotational Atherectomy System, involving a manufacturing-process change for its Short Drive Laser/Advancer assembly.
• In February 2026, the FDA approved a PMA supplement covering the Diamondback 360 and Diamondback 360 Precision Coronary Orbital Atherectomy Systems, relating to microbiology testing processes.

Major Growth Drivers Shaping the Future of United States Atherectomy Devices Sector

1. Rising Peripheral Artery Disease Burden Creates a Larger Treatment Pool

The expanding prevalence of peripheral artery disease is a fundamental growth catalyst for the U.S. atherectomy devices market. PAD develops when arteries supplying the limbs become narrowed or blocked, most commonly because of atherosclerotic plaque. The CDC estimates that around 6.5 million Americans aged 40 and older have PAD, with risk increasing with age and conditions such as diabetes, hypertension, high cholesterol, and smoking. As the population ages and chronic metabolic disorders remain widespread, the number of patients requiring vascular evaluation and revascularization is expected to remain substantial. Atherectomy can be particularly valuable when plaque burden or calcification complicates balloon angioplasty. Growing awareness, earlier diagnosis, and improved referral pathways can therefore expand the pool of patients considered for plaque-modification procedures.

In May 2025, BD announced the XTRACT real-world registry for its Rotarex Atherectomy System, designed to evaluate outcomes among U.S. PAD patients across approximately 100 clinical sites.

2. Advanced Laser and Mechanical Technologies Expand Procedural Capabilities

Technological innovation is strengthening the competitive landscape for atherectomy devices in the United States. Manufacturers are developing systems that offer greater flexibility in treating different lesion types, lengths, anatomical locations, and degrees of calcification. Laser platforms can vaporize plaque, while rotational and orbital technologies mechanically modify lesions. Directional systems can provide targeted plaque removal and controlled tissue excision. These innovations can improve vessel preparation and help physicians manage complex peripheral lesions that may otherwise be challenging to treat with conventional angioplasty alone. Continued clinical research is also important because physicians increasingly seek evidence supporting safety, effectiveness, and procedural efficiency. The growing emphasis on differentiated device profiles, smaller catheter sizes, improved access options, and expanded indications should encourage adoption across specialized vascular centers.

In January 2025, AngioDynamics initiated the AMBITION BTK randomized trial and registry evaluating the Auryon Atherectomy System for challenging below-the-knee lesions associated with critical limb ischemia.

3. Shift Toward Minimally Invasive and Ambulatory Vascular Care

The growing preference for minimally invasive vascular interventions is creating favorable conditions for atherectomy device adoption. Hospitals, outpatient departments, and ambulatory centers increasingly seek procedures that can provide effective revascularization while supporting shorter recovery periods and efficient resource utilization. Atherectomy technologies fit this trend because they are catheter-based and can be integrated into endovascular treatment strategies. Research examining peripheral vascular interventions has found that atherectomy use was particularly associated with procedures performed in office-based and ambulatory settings. Technological improvements, including smaller profiles and alternative vascular access approaches, are further supporting procedural flexibility. As vascular specialists expand outpatient treatment pathways and healthcare providers focus on operational efficiency, demand for devices suitable for minimally invasive plaque modification is likely to increase.

In January 2024, AngioDynamics received FDA 510(k) clearance for the 225-cm Auryon XL radial-access catheter, expanding access options for Auryon atherectomy procedures.

Critical Challenges Facing the United States Atherectomy Devices Industry

1. High Device Costs and Reimbursement Complexity

The high acquisition cost of sophisticated atherectomy platforms can constrain adoption, particularly among smaller hospitals, ambulatory centers, and facilities operating under strict capital and procedural budgets. Laser, orbital, and rotational systems may require specialized equipment, disposable components, physician training, and dedicated procedural infrastructure. Healthcare providers therefore assess clinical value against reimbursement levels and total procedural costs before adopting new platforms. Reimbursement complexity can also vary according to procedure type, care setting, payer, and patient characteristics. Although atherectomy may provide important benefits for selected lesions, physicians and administrators must demonstrate that additional device costs are justified by clinical outcomes and operational efficiencies. These financial considerations can slow penetration in price-sensitive facilities and contribute to uneven adoption across U.S. regions.

2. Clinical Complexity and Physician Training Requirements

Atherectomy procedures require specialized expertise because inappropriate device selection, aggressive plaque modification, or inadequate lesion assessment can increase procedural risks. Operators must understand differences between directional, rotational, orbital, and laser technologies and determine which platform is appropriate for individual lesion characteristics. Complex calcified disease, long lesions, chronic total occlusions, and below-the-knee disease can further increase procedural difficulty. Consequently, healthcare facilities may require structured physician training, specialized teams, and continued experience before adopting advanced systems. Clinical evidence and physician confidence also influence purchasing decisions. Variations in operator experience and institutional protocols can result in differences in atherectomy utilization across regions, potentially limiting consistent market penetration despite the underlying need for peripheral vascular interventions.

California — Innovation Meets a Vast Vascular Care Ecosystem

California represents an attractive market for atherectomy devices because of its large healthcare ecosystem, extensive specialist network, and strong concentration of advanced medical technology companies. The state supports a broad range of hospitals, cardiovascular centers, outpatient facilities, and academic institutions capable of adopting sophisticated endovascular technologies. California's aging population and burden of chronic conditions create a continuing need for vascular disease management. The state is also an important innovation hub, encouraging collaboration between medical-device developers, physicians, research institutions, and healthcare providers. Such an environment can accelerate awareness and clinical evaluation of advanced atherectomy platforms. The presence of specialized vascular centers may particularly support adoption of laser, orbital, rotational, and directional systems for complex lesions. California's technology-oriented healthcare environment therefore offers manufacturers opportunities for clinical partnerships, product development, training, and market expansion.

Texas — The High-Volume Frontier for Peripheral Intervention

Texas offers significant opportunities for atherectomy device manufacturers due to its extensive hospital network, large patient population, and substantial outpatient healthcare infrastructure. The state maintains a broad database of hospital and ambulatory surgery activity, including outpatient surgeries and radiological procedures, demonstrating the scale of its procedural healthcare environment. Large metropolitan healthcare clusters in Houston, Dallas–Fort Worth, San Antonio, and Austin provide important centers for cardiovascular and vascular interventions. The prevalence of risk factors associated with PAD, including diabetes and cardiovascular disease, can support demand for peripheral vascular treatment. Texas also has a substantial network of specialty physicians and tertiary-care facilities capable of performing advanced endovascular procedures. Increasing use of minimally invasive treatment and expansion of ambulatory care can further create opportunities for compact, versatile atherectomy platforms. Manufacturers may benefit from physician education, hospital partnerships, and targeted expansion across major metropolitan and regional healthcare centers.

New York — Dense Healthcare Networks Power Advanced Vascular Care

New York presents a strong opportunity for atherectomy devices because cardiovascular disease remains a major health burden and the state has a dense network of hospitals, academic medical centers, vascular specialists, and outpatient providers. The New York State Department of Health reported that cardiovascular disease was the state's leading cause of death, accounting for 29% of deaths statewide in its February 2025 update. It also estimated that approximately 1.298 million adults reported cardiovascular disease. This burden creates a substantial clinical environment for advanced vascular intervention. New York City's concentration of major medical institutions can support adoption of innovative atherectomy technologies, while providers elsewhere in the state can expand access to minimally invasive peripheral interventions. Clinical research, physician training, and sophisticated catheterization infrastructure may further support adoption of directional, laser, rotational, and orbital devices.

Florida — An Aging Population Fuels Demand for Vascular Solutions

Florida is a strategically important market for atherectomy devices because its large and aging population creates sustained demand for cardiovascular and peripheral vascular care. Older adults have a greater likelihood of developing atherosclerosis and PAD, making Florida's demographic profile favorable for vascular intervention technologies. The state's extensive network of hospitals, cardiovascular centers, outpatient facilities, and specialty practices provides multiple channels for atherectomy adoption. Growth in minimally invasive procedures can also encourage healthcare providers to evaluate catheter-based plaque-modification technologies as alternatives or complements to conventional treatment approaches. Florida's large metropolitan areas, including Miami, Tampa, Orlando, and Jacksonville, offer concentrated healthcare markets, while regional hospitals extend treatment availability beyond major cities. Device companies can strengthen penetration through physician education, clinical evidence generation, ambulatory-care partnerships, and product demonstrations focused on complex lesion management. The combination of demographic demand and extensive healthcare infrastructure makes Florida an important U.S. growth market.

United States Directional Atherectomy Devices Market — Precision Plaque Removal Takes Center Stage

Directional atherectomy devices are designed to selectively cut and remove plaque from within an artery, providing physicians with controlled plaque excision and vessel preparation. Their ability to target eccentric or localized lesions makes them valuable for selected peripheral interventions. Demand is supported by the growing prevalence of PAD, particularly among older adults and patients with diabetes and other cardiovascular risk factors. Directional systems can be attractive where physicians require targeted debulking before balloon angioplasty or other revascularization strategies. The segment is also benefiting from ongoing improvements in catheter profiles, maneuverability, and lesion access. However, adoption depends heavily on operator expertise, clinical evidence, reimbursement considerations, and competition from laser, orbital, and rotational technologies. Increasing interest in personalized lesion preparation and minimally invasive vascular care should support continued opportunities for directional atherectomy systems in the United States.

United States Cardiovascular Atherectomy Devices Market — Advanced Plaque Modification Supports Complex Interventions

The cardiovascular atherectomy devices market in the United States is supported by the need to manage atherosclerotic and heavily calcified vascular lesions that can complicate conventional intervention. Atherectomy technologies can modify or remove plaque, helping physicians prepare vessels before subsequent treatment. Rising cardiovascular disease burden, aging demographics, diabetes, hypertension, and other risk factors contribute to continued demand for advanced vascular interventions. New technologies are increasingly designed to improve procedural flexibility, lesion crossing, plaque removal, and access. Clinical evidence is also influencing adoption as healthcare providers seek data demonstrating safety and effectiveness. Research has shown substantial regional variability in atherectomy utilization, with lesion calcification and care setting influencing use. Consequently, manufacturers are focusing on physician training, clinical studies, improved device profiles, and expanded indications to increase utilization across U.S. cardiovascular and vascular care settings.

United States Ambulatory Care Service Atherectomy Devices Market — Outpatient Vascular Care Opens New Growth Channels

The ambulatory care segment is becoming increasingly relevant to the U.S. atherectomy devices market as healthcare providers seek efficient, minimally invasive approaches for appropriate peripheral vascular procedures. Office-based laboratories and ambulatory centers can offer convenient treatment environments while supporting streamlined patient pathways. Evidence from U.S. peripheral vascular intervention research found that atherectomy use was strongly associated with office-based and ambulatory settings compared with hospital-based procedures. This trend creates opportunities for devices with compact profiles, straightforward operation, flexible access options, and efficient procedural workflows. Manufacturers are consequently emphasizing technologies that can support outpatient vascular intervention while maintaining clinical performance. Expansion of physician-led vascular centers, improvements in radial and alternative access techniques, and growing emphasis on healthcare cost efficiency could further increase demand. Reimbursement policies, facility capabilities, physician expertise, and patient selection will remain important factors shaping the segment.

Market Segmentations

Product Type

• Directional
• Rotational
• Orbital
• Laser

Application

• Cardiovascular
• Neurovascular
• Peripheral Vascular

End User

• Hospitals
• Ambulatory Care Service
• Medical Research Institutes

Top States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All Key Players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

1. Boston Scientific Corporation, Inc.
2. Abbott Laboratories
3. Medtronic plc
4. Cardinal Health
5. Terumo Corporation
6. Integer Holdings Corporation
7. Becton, Dickinson and Company
8. AngioDynamics Inc.

Report Details: